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Summary
BACKGROUND: The number of individuals with autoim-
mune inflammatory rheumatic diseases (AIIRDs) treated
with immunosuppressive drugs is increasing steadily. The
variety of immunosuppressive drugs and, in particular, bio-
logical therapies is also rising. The immunosuppressants,
as well as the AIIRD itself, increase the risk of infection
in this population. Thus, preventing infections by means of
vaccination is of utmost importance. New Swiss vaccina-
tion recommendations for AIIRD patients were initiated by
the Swiss Federal Office of Public Health and prepared by
a working group of the Federal Commission for Vaccina-
tion Issues as well as by consultation of international ex-
perts.
METHODS: A literature search was performed in elec-
tronic databases (Cochrane, Medline, PubMed, Embase).
In addition, unpublished literature was identified through a
targeted website search of relevant organisations and inter-
national conferences dealing with vaccination, infectious
diseases and rheumatology.
RESULTS: Although data are scarce, the following main
points were retrieved from the literature. Inactivated vac-
cines are safe, but their immunogenicity may be reduced in
AIIRD patients, especially if they are under immunosup-
pressive therapy. Rituximab and abatacept appear to reduce
significantly immune responses after vaccination. Live vac-
cines are generally contraindicated under immunosuppress-
ive therapy owing to safety concerns. Specific exceptions,
as well as time intervals for the administration of live vac-
cines after interruption of an immunosuppressive therapy,
have been formulated in this article.
CONCLUSION: More evidence regarding the immuno-
genicity and safety of vaccinations in AIIRD patients under
various therapies is needed. Vaccination recommendations
should be updated on a regular basis, as more scientific
data will become available.
Key words: rheumatic disease; immunosuppression;
vaccination; immunocompromised; infection;
autoimmunity
Introduction
In Europe, an estimated 2% of the adult population suffers
from an autoimmune inflammatory rheumatic disease
(AIIRD) [10]. With a population of around 740 million,
this amounts to approximately 15 million individuals in
Europe. Patients with AIIRD are at an increased risk of in-
fections, and vaccinations as an important means for pre-
vention are indicated in this vulnerable population. The use
of immunosuppressive drugs has increased in recent years
in these patients [11]. As a result of different immunosup-
pressive medications the immunogenicity of vaccines may
be reduced. Furthermore, the administration of live vac-
cines bears the potential risk of invasive infection with the
attenuated vaccine strain, and should generally be avoided
under immunosuppressive therapy; in most international
guidelines, live vaccines are contraindicated under immun-
osuppressive therapy with a systemic effect [1, 2, 4, 12].
In Switzerland, vaccination recommendations for AIIRD
patients were published in 2010 by the Swiss Society of
Rheumatology [6]. In recent years, new disease-modifying
medications, and biological agents, in particular, have been
approved for the treatment of AIIRD patients. The growing
experience with vaccinations under different immunosup-
pressive regimens allows the previous recommendations to
be updated.
The formulation of new recommendations was initiated by
the Swiss Federal Office of Public Health (FOPH) and pre-
pared by a working group of the Federal Commission for
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Vaccination Issues. The main principles were published in
the bulletin of the FOPH in February 2014 [13]. Here we
present the background information that forms the basis of
the article published by the FOPH, as well as detailed prac-
tical recommendations. The recommendations are based on
an extensive literature search. As scientific data on many
aspects are still scarce, the majority of recommendations
given in this article are based on clinical experience and ex-
pert opinion of a diverse group of specialists in the fields of
rheumatology, immunology, infectiology, travel medicine
and vaccination. Specific advice is given regarding tim-
ing of vaccinations in relation to different medications, as
well as certain circumstances and approaches under which
live vaccines may be considered during immunosuppress-
ive therapy.
Methodology
These new recommendations were initiated by the Swiss
Federal Office of Public Health and prepared by a working
group of the Federal Commission for Vaccination Issues.
This panel was composed of members with a wide breadth
of specialties (immunology, infectious diseases, vaccino-
logy, travel medicine, rheumatology). Drafts were distrib-
uted to panel members for comments and were discussed
in four in-person meetings. The recommendations were
reviewed by the Swiss Society of Rheumatology and by
the Swiss Society for Allergology and Immunology. Na-
tional and international experts in the field of vaccination
recommendations in immunocompromised persons were
consulted in the process and were composed of immunolo-
gists, rheumatologists, infectiologists and travel medicine
experts.
The GRADE approach was applied to rate the quality of
evidence (QoE) as well as the strength of recommendation
(SoR) [14]. Quality of evidence has four categories: “high
quality”, “moderate quality”, “low quality” and “very low
quality”. When no published evidence could be found, it
was stated as “grade of evidence not possible“. The
strength of recommendation was categorised into “strong”
and “weak”.
Search strategy
Published evidence was searched for in electronic data-
bases (Cochrane, Medline, PubMed, Embase). Unpub-
lished (grey) literature (unpublished reports, conference
abstracts) was retrieved through a targeted website search
of relevant organisations (including international vaccin-
ation recommendations such as recommendations by: the
United States Centers for Disease Control and Prevention
[1], the European League Against Rheumatism (EULAR)
[2], the Infectious Diseases Society of America (IDSA) [3]
several European countries [4–8] and others [9]) and inter-
national conferences dealing with vaccination, infectious
diseases and rheumatology. Additional articles were iden-
tified through reference lists of selected papers. Literature
published up to 29 January 2014 was reviewed and ana-
lysed.
The search terms from box 1 were used in combination.
Only literature on adult AIIRD were included, with the
exception of literature on live vaccine, such as measles,
mumps, rubella and varicella, in which case the majority
of data were available for paediatric patients. Mostly Eng-
lish and German articles were included. A summary of all
relevant papers was produced. Only data from meta-ana-
lyses, systematic reviews, randomised trials, and observa-
tional studies were taken into account. Case reports were
not included in this review with the exception of two case
series on live vaccination under immunosuppression ther-
apy and of adverse reactions to pneumococcal polysacchar-
ide vaccine in patients with Behçet’s disease by Hugle et
al. [15], which was considered to report important inform-
ation.
Articles were screened for information on increased risk of
infection, vaccine-preventable infections, safety of vaccin-
ations, immunogenicity of vaccination, timing of vaccina-
tion in relation to disease activity, timing of vaccination in
relation to medication, effects of additional vaccine doses.
Box 1: Search terms ‒ autoimmune inflammatory
rheumatic diseases, infections and vaccines considered
in the literature search
Autoimmune inflammatory rheumatic diseases:
“rheumatology”, “rheumatic”, “AIIRD”, “autoimmune”,
“immunocompromised”, “autoimmune inflammatory
rheumatic disease”, “rheumatoid arthritis”, “lupus eryth-
ematosus”, “spondylarthritis”, “spondyloarthritis”, “vas-
culitis”, “connective tissue disease”, “ scleroderma”,
“systemic sclerosis”, “Behҫet’s disease”, “Wegener
granulomatosis”, “Churg-Strauss syndrome”, “dermat-
omyositis”, “polymyositis”, “polyarteriitis nodosa”
“Takayasu arteritis”, “giant cell arteritis”, “psoriatic
arthritis”
Infections: “infection”, “risk of infection”, “tetanus”,
“diphtheria”, “poliomyelitis”, “polio”, “pertussis”, “hep-
atitis A”, “hepatitis B”, “haemophilus influenza b”, “yel-
low fever”, “mumps”, “measles”, “rubella”, “varicella”,
“herpes zoster” “rabies”, “tick borne encephalitis”,
“TBE”, “Japanese encephalitis”, “cholera”, “human
papillomavirus”, “HPV”, “typhoid fever”, “meningococ-
cal” “pneumococcal”, “influenza”, “H1N1”, “tubercu-
losis”
Vaccines: “vaccination”, “vaccine”, “vaccination
guideline”, “inactivated vaccin*”, “live vaccin*”, “con-
jugate vaccin*”, “polysaccharide vaccin*”, “tetanus vac-
cin*”, “diphtheria vaccin*”, “poliomyelitis vaccin*”,
“polio vaccin*”, “pertussis vaccin*”, “hepatitis A vac-
cin*”, “hepatitis B vaccin*”, “haemophilus influenza b
vaccin*”, “yellow fever vaccin*”, “mumps vaccin*”,
“measles vaccin* ”, “rubella vaccin*”, “varicella vac-
cin*”, “herpes zoster vaccin*” “rabies vaccin*”, “tick
borne encephalitis vaccin*”, “TBE vaccin*”, “Japanese
encephalitis vaccin*”, “cholera vaccin*”, “human papil-
lomavirus vaccin*”, “HPV vaccin*”, “typhoid fever vac-
cin*”, “meningococcal vaccin*” “pneumococc* vac-
cin*”, “influenza vaccin*”, “H1N1 vaccin*”, “tubercu-
losis vaccin*”, “BCG”
BCG = Bacille Calmette-Guérin; HPV = human papillo-
mavirus; TBE = tick-borne encephalitis
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Results
Increased risk of infection
Infections are a substantial cause of morbidity and mor-
tality in persons with autoimmune inflammatory rheumatic
diseases [16]. The risk of infection may be increased by the
disease itself [17–19], but also by the use of immunosup-
pressive and immunomodulatory drugs [20–27, 188]. In the
following chapters, the term “immunosuppressive therapy”
will include both “immunosuppressive” and “immunomod-
ulatory” therapy.
In patients with AIIRD, the risk of acquiring a confirmed
infection can be 1.7 times higher than in the general pop-
ulation [28]. Not only is the risk of infection higher in
AIIRD patients, but also the course of infection can be
more severe [29, 30]. In particular, the risk of an infection
requiring hospitalisation has been shown to be 1.8 times
higher in patients with AIIRD compared with healthy per-
sons [28].
Increased risk of vaccine-preventable infections
Patients with AIIRD have an increased risk for influenza
infection [31–33], invasive pneumococcal disease [34, 35],
and for herpes zoster [36–40]. Several studies have demon-
strated that the risk of tuberculosis infection is higher in
rheumatoid arthritis (RA) and systemic lupus erythem-
atosus (SLE) patients compared to the general population
[41–45]. Also the risk of human papillomavirus (HPV) in-
fection [46] and the incidence of cervical dysplasia are in-
creased in SLE patients, while clearance of the virus is
decreased compared with the general population [47]. He-
patitis B reactivation can be severe and can sometimes have
a high mortality in patients under immunosuppressive ther-
apy (esp. during the tapering process [48]).
Sixteen key recommendations have been formulated (box
2) and will be elaborated in the following sections.
Box 2: Key recommendations
1. Benefits of vaccination greatly outweigh the risks
of infection and vaccinations do not cause autoim-
mune inflammatory rheumatic diseases, nor their
exacerbations.
2. There are no specific contraindications for vaccina-
tion with inactivated and live vaccines in patients
with autoimmune inflammatory rheumatic disease
without immunosuppressive treatment.
3. The vaccination status of the patients should be as-
sessed and documented at the earliest time point
after diagnosis and recommended vaccinations
should be administered as soon as possible. If pos-
sible, vaccinate before initiation of immunosup-
pressive therapy. Live attenuated vaccines should
be given at least four weeks before initiation of im-
munosuppressive treatment.
4. The immune response to a booster vaccine admin-
istered during immunosuppressive treatment is con-
sidered to be less affected than the response to a
primary vaccine dose.
5. In already treated AIIRD patients, vaccines should
ideally be administered when immunosuppressive
therapy is lowest.
6. It is generally safe to administer inactivated vac-
cines to patients with AIIRD under immunosup-
pressive treatment; the immunogenicity may be re-
duced.
7. The administration of live vaccines to immunosup-
pressed patients bears the risk of replication of the
attenuated micro-organism and invasive infections.
Live vaccines with a high potential of replication
(e.g. yellow fever vaccine) should generally be
avoided in patients with autoimmune inflammatory
rheumatic disease under treatment with a systemic
immunosuppressive effect; specific exceptions ap-
ply. Live vaccines with a low risk of replication
(typhoid oral vaccine, varicella / herpes zoster vac-
cine) may be used with caution in selected patients
under immunosuppressive therapy.
8. Depending on the drug, different intervals after in-
terrupting immunosuppressive treatment are ad-
vised before immune reconstitution has been estab-
lished.
9. General recommendations for basic vaccinations
also apply to patients with AIIRD.
10. Specific vaccinations are recommended for AIIRD
patients as they may require more comprehensive
protection: These include the annual influenza vac-
cination and the pneumococcal vaccination. The
use of the 13-valent pneumococcal conjugate vac-
cine (Prevenar®) should be preferred to the
23-valent polysaccharide vaccine. Vaccination
against hepatitis B is encouraged in all AIIRD pa-
tients and vaccination against human papillomavir-
us in female patients with systemic lupus erythem-
atosus aged 11–26 years. Herpes zoster vaccination
will be recommended in AIIRD patients aged >50
years when the vaccine becomes available in
Switzerland.
11. Four to six weeks after a completed primary course
of vaccination, serology testing should be per-
formed if the corresponding serological test is
available.
12. In a patient undergoing immunosuppressive therapy
and in whom immunity towards measles, rubella
and varicella is unknown, a specific serological test
should be performed. The same approach should be
followed in a person under immunosuppressive
therapy who received the yellow fever vaccination
in the past and intends to travel to a yellow fever en-
demic area.
13. As the immunocompromised person may not be
protected against diseases despite previous vaccina-
tion (e.g. against mumps, measles, rubella, vari-
cella, influenza), insist on checking the vaccination
status of their household and other close contacts,
and vaccinate if indicated.
14. If the immunocompromised person is not protected
against measles and/or varicella and has contact
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with an infected person, consider immuno-
globulins/antivirals.
15. Always use conjugate vaccines in preference to
polysaccharide vaccines because they induce higher
affinity antibody responses, longer lasting immune
responses and memory responses.
16. Vaccination should preferentially be administered
during stable disease.
1. Vaccination does not trigger autoimmune
inflammatory rheumatic diseases, nor their
exacerbations (QoE: low, SoR: strong), some
autoimmune conditions have been associated with
specific vaccines
A causal relationship between vaccination and autoimmune
diseases has been debated at great length in the literature
[49, 50]. There is no reliable evidence that autoimmune
diseases are caused by vaccination. Nevertheless, specific
vaccines have been associated with autoimmune reactions,
for example Guillain Barré syndrome (GBS) after 1976
swine influenza A (H1N1) subtype A/NJ/76 vaccination in
the United States [51]. An increase in GBS cases after in-
fluenza A (H1N1) 2009 monovalent vaccination was repor-
ted (around 1 excess case in 1 million vaccinated doses)
and an association with the vaccine has not been ruled out
[26, 52–60]. An increase of Guillain Barré syndrome was
also reported in patients having received brain-derived ra-
bies vaccine, which is not in use in Europe [61, 62].
An association between mumps/measles/rubella (MMR)
vaccine and immune thrombocytopenic purpura (ITP) was
also reported (around 1 case per 22,300–50,000 doses)
[63–65], although a second MMR dose was not associated
with an increased risk of ITP [66, 67].
Some have also suspected vaccine adjuvants of triggering
autoimmune diseases (autoimmune/inflammatory syn-
drome induced by adjuvants (ASIA) [68–70]). An associ-
ation has not been demonstrated to date [71–73] with the
exception of AS03 adjuvanted H1N1 influenza vaccine,
which has been suspected to be associated with narcolepsy
in Finland, Sweden, Norway, Ireland, and the United King-
dom [74, 75]. The association was most pronounced in
children.
In conclusion, few vaccines were found to be associated
with autoimmune reactions and they are suspected to be
linked to specific antigens. Importantly, the risk of GBS
and other immune diseases is increased by infection. For
example, the risk of GBS within 90 days after influenza-
like illness was found to be 7-fold increased (risk ratio
7.35, 95% CI 4.36–12.38) [76] and the risk of GBS after
influenza infection is 4–7 times higher than after influenza
vaccination [77].
In conclusion, it is important to consider the overall risks
and benefits of vaccination, as defined by epidemiological
studies. Clinicians, policy makers and those eligible for
vaccination should be assured that the benefits of most vac-
cines greatly outweigh the risks of infection.
Similarly, exacerbations of rheumatic diseases after vaccin-
ation have been extensively discussed in the literature and
there are several case reports of worsening disease symp-
toms after vaccination. However, the majority of published
data support the conclusion that immunisation with inactiv-
ated vaccines is safe and does not increase disease activ-
ity in AIIRD patients, measured by clinical and biological
means [78–81]. Several studies in patients with rheumat-
oid arthritis, connective tissue disease, spondyloarthritis,
and systemic vasculitis showed that the administration of
influenza, pneumococcal, tetanus toxoid, Haemophilus in-
fluenzae type b, hepatitis A, hepatitis B and human papil-
lomavirus vaccine was safe and did not increase disease
activity [79, 82, 83]. It should be noted that most vaccina-
tion studies in AIIRD patients were performed in patients
with stable disease (please see section 16).
2. There are no specific contraindications to
administering inactivated or live vaccines in AIIRD
patients without immunosuppressive treatment (QoE:
high, SoR: strong)
A patient with untreated AIIRD, i.e. who is not under sys-
temic immunosuppressive therapy, should be vaccinated
like any other person, although the clinical assessment of
the individual patient has to be taken into account. Therapy
with hydroxychloroquine or sulfasalazine is not considered
to be immunosuppressive or influence vaccine immune
responses, although a possible interference of hydroxy-
chloroquine in the case of intradermal vaccination has been
observed [84]. Of note, prophylactic paracetamol adminis-
tration has also been shown to reduce antibody responses
after vaccination in children [85].
Furthermore, additional vaccinations for patients with
chronic diseases are recommended as a result of the in-
creased risk of infections or their complications.
Of note, in a recent case series, severe local reactions and
severe systemic inflammatory responses to 23-valent poly-
saccharide pneumococcal vaccine (23-PPV) were observed
in patients with Behçet’s disease under treatment with
abatacept/prednisolone, etanercept, azathioprine or sole
anti-inflammatory drugs [15]. No such adverse reactions
were seen in patients with other autoimmune or autoin-
flammatory diseases receiving 23-PPV vaccine. It was pos-
tulated that the presumed auto-inflammatory mechanism
underlying Behçet’s disease could be responsible for the
severe adverse events after pneumococcal vaccination.
Owing to this potential streptococcal hypersensitivity reac-
tion, caution is warranted when giving pneumococcal vac-
cination to patients with Behçet’s disease.
3. The vaccination status should be assessed and
documented as soon as the diagnosis of an autoimmune
disease is made and immunisations should be
performed whenever possible before
immunosuppressive treatment is started (QoE: grade
of evidence not possible, SoR: strong)
Ideally, the vaccination status of the patients should be as-
sessed and documented at the earliest time point after dia-
gnosis, and recommended vaccinations should be admin-
istered as soon as possible. If possible, vaccines should be
administered before initiation of immunosuppressive ther-
apy. Furthermore, if live attenuated vaccines are admin-
istered, the start of immunosuppressive therapy must be
delayed for at least 4 weeks. Inactivated vaccines should
ideally also be given at least 4 weeks before starting high-
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dose systemic corticosteroids or immunosuppressive med-
ication.
There are three main reasons for assessing the vaccination
status of patients with AIIRDs as soon as possible: (i) some
AIIRDs per se confer an increased risk of infection and
vaccinations should be updated as soon as possible after
diagnosis; many patients do not immediately receive im-
munosuppressive treatment and thus vaccines can be ad-
ministered at a time point when (ii) the immunogenicity of
vaccination is not compromised by the immunosuppression
and (iii) live vaccines can be safely administered.
4. The immune response to a booster vaccine
administered during immunosuppressive treatment is
considered to be less affected than a primary vaccine
dose (QoE: low, SoR: strong)
Immunosuppressive drugs interfere with the activation and
clonal expansion of T and B cells. As a result, the immune
response to a primary vaccine dose can be impaired. The
T and B cell immune response to a vaccine booster dose is
generally better preserved as more memory B and T cells
(induced by the first vaccine dose) are present [86, 87].
Thus, a booster vaccination in a person under immunosup-
pressive therapy will usually generate protective antibody
levels, although antibody responses may be lower and pro-
tection shorter than in persons without immunosuppressive
treatment. It has been shown that for a booster tetanus vac-
cine dose immune responses were preserved under various
immunosuppressive therapies [88, 89].
5. In already-treated AIIRD patients vaccines should
ideally be administered when the immunosuppressive
therapy is lowest (QoE: low, SoR: strong)
The immunogenicity of vaccines may be reduced by an
immunosuppressive therapy. The effect can be expected
to be dependent on the total taken dose. To achieve the
best protection, patients under immunosuppressive ther-
apies should be vaccinated when the dosage is lowest.
Furthermore, live vaccines bear the risk of a potential rep-
lication of the attenuated virus and are thus generally con-
traindicated under immunosuppressive therapies. Under
specific circumstances live vaccines may be administered
(sections 7 and 8).
6. It is generally safe to administer inactivated
vaccines, also to AIIRD patients under
immunosuppressive treatment; the immunogenicity
may be reduced (QoE: moderate, SoR: strong)
The majority of published data show that the administra-
tion of inactivated vaccines to AIIRD patients under im-
munosuppressive therapy is safe [16, 90]. Their adminis-
tration was not associated with a higher risk of vaccine
reactions, nor with a worsening or reactivation of the un-
derlying disease (see section 1).
The immunogenicity of vaccinations during the use of non-
biological disease-modifying antirheumatic drugs
(DMARDs), corticosteroids and/or biological agents has
been studied in patients with rheumatoid arthritis, spon-
dyloarthritis, connective tissue disease, and vasculitis. Data
exist on the immunogenicity of seasonal influenza, pan-
demic influenza (H1N1), pneumococcal polysaccharide,
pneumococcal conjugate, hepatitis A, hepatitis B, tetanus
toxoid, Haemophilus influenzae b and human papillo-
mavirus vaccination [91]. Most studies showed slightly
reduced, but sufficient immune responses following vac-
cination of patients with AIIRD under therapy with cor-
ticosteroids, non-biological DMARDs (with the exception
of methotrexate) and tumour necrosis factor (TNF) block-
ers (table 1).
However, it was shown in several studies that methotrexate
blunted the response to influenza, pneumococcal vaccin-
ation, tetanus and hepatitis A vaccination [89, 92–95]. A
combination therapy of TNFα blocking agents and me-
thotrexate appeared to decrease serological responses even
further [92, 96, 97].
One study suggests that the immunogenicity of inactivated
vaccines may be preserved when administered on the same
day as infusion of the TNF inhibitor infliximab (IFX), but
may be hampered when administered several weeks after-
wards, when the full immunosuppressive effect has deve-
loped. This effect was observed in rheumatoid arthritis pa-
tients, but patients with ankylosing spondylitis developed
good antibody responses independent of the time of vac-
cination in relation to IFX infusion [98]. For now, inactiv-
ated vaccinations should be applied regardless of timing of
IFX, as most studies have shown sufficient immunogeni-
city of inactivated vaccinations under sole IFX treatment
[94, 99–101]. More data will be necessary for a reliable re-
commendation regarding the timing of vaccination and in-
fliximab infusions.
Abatacept is a fusion protein composed of the extracellular
domain of cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) and the IgG1 Fc, which blocks the interaction
between the surface molecules CD80/86 on an activated
antigen-presenting cell and CD28 on T cells and inhibits
T cell activation. It has been shown to reduce significantly
the humoral immune response to influenza, pneumococcal
and tetanus toxoid vaccination [102, 103]. In healthy sub-
jects receiving abatacept, this effect was most severe when
the vaccination was administered 2 weeks after a single
dose of abatacept treatment. If vaccination was given be-
fore abatacept, the effect was minor [104–106]. In contrast,
tocilizumab (a humanised monoclonal antibody that binds
soluble as well as membrane-bound interleukin-6 receptors
and thereby blocks the proinflammatory effects of inter-
leukin-6) does not seem to affect the immunogenicity of in-
fluenza, pneumococcal conjugate, pneumococcal polysac-
charide or tetanus vaccination [107–111].
Most impressively, humoral immune responses to influ-
enza and pneumococcal vaccination were nearly absent in
the 6 months after rituximab administration due to the tran-
sient loss of immunocompetent B cells [112, 113]. (Ritux-
imab [RTX] is a chimeric monoclonal antibody directed
against CD20, a molecule expressed specifically on B
cells.) Also, administering rituximab in the weeks after im-
munisation may compromise vaccine responses. Immuno-
genicity seems to be partly restored 6‒8 months after RTX
therapy [113].
As a general rule, the immunogenicity of vaccinations may
be reduced under immunosuppressive therapy. Nonethe-
less, vaccination of AIIRD patients under immunosup-
pressive treatment with inactivated vaccines is generally
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Table 1: Published evidence on immunogenicity of inactivated vaccines in different rheumatic disease groups and for various immunosuppressive agents.
No medication Corticosteroids MTX Other DMARDs MTX + TNFi TNFi RTX Abatacept Tocilizumab
RA Good
immunogenicity
[88, 98, 99, 101,
114–118].
Good to
moderate
immunogenicity
[98, 99,
113–116, 118,
119], with
reduced level of
humoral
immune
response [110,
117].
Good
immunogenicity
[88, 98, 99, 101,
113-116, 118].
Reduced
immunogenicity
(MTX +
certolizumab)
(47.4%) [97].
Good [99–101, 115,
120] to moderate
immunogenicity [98].
Immunogenicity
dependent on time
point of vaccination in
relation to infliximab
treatment.
Reduced
immunogenicity in
[116, 119],
immunogenicity
reduced under
certolizumab [97].
Reduced to
blunted immune
response, in
particular if
vaccine given
close to RTX
administration
[113, 118, 121].
Reduced
immunogenicity
[106].
Good
immunogenicity
[108, 110].
CTD Good [115, 122]
to moderate
immunogenicity
[123]. Reduced
immunogenicity
in [124, 125] (no
neg. effect by
corticosteroids).
Reduced
immunogenicity
in [126].
Good
immunogenicity
[115].
Reduced
immunogenicity
[125] (neg.
effect of MTX).
AZA had a negative
effect on humoral
vaccine responses
[124].
Moderate [123] to
good immunogenicity
[115].
SpA Good
immunogenicity
[116] (n = 1).
Good
immunogenicity
[116] (n = 1).
Good
immunogenicity
[116] (n = 1).
Moderate [116] to
good immunogenicity
[98].
Seasonal
influenza
VAS Good
immunogenicity
in WG patients
[127].
Good
immunogenicity in
WG patients [127,
128].
RA Reduced
immunogenicity
[103, 129–133];
no neg. effect by
corticosteroids).
Reduced
immunogenicity
[103, 129, 134,
135]. Reduced
immunogenicity
in [132] (no
neg. effect by
MTX). A 2nd
vaccine dose
achieved good
vaccine
responses
[129].
Reduced
immunogenicity
under AZA,
leflunomide, MMF,
CYC. A 2nd
vaccine dose
achieved good
vaccine responses
[129].
Reduced
immunogenicity [132,
133].
Reduced
immunogenicity [129,
131] (no neg. effect by
TNFi).
Reduced
immunogenicity
[103, 129].
Recent RTX
treatment had a
negative effect
[129]. Severely
reduced
immunogenicity
in [136].
Severely
reduced
immunogenicity
[102, 103].
Good
immunogenicity
[103].
CTD Reduced
immunogenicity
[134], for
seroconversion
and GMT fold
increase,
international
immunogenicity
criteria were
met.
Reduced
immunogenicity
[123, 129, 130,
134] (no neg.
effect by
corticosteroids).
A 2nd vaccine
dose achieved
good vaccine
responses [129,
135].
Immunogenicity
was decreased
[103, 129, 134,
135]. A 2nd
vaccine dose
achieved good
vaccine
responses [129,
135].
Reasonable [123]
to decreased
immunogenicity
[103, 129, 130,
134, 135]. A 2nd
vaccine dose
achieved good
responses [129,
135]. Under
chloroquine, good
immunogenicity
[134].
Overall reduced
immunogenicity [103,
129], but not
demonstrated for
TNFi.
Reduced
immunogenicity
[103, 129]. In
[129], recent
RTX treatment
(<12 weeks)
had a negative
effect on
immunogenicity.
Reduced
immunogenicity
[103].
Pandemic
Influenza
SpA Good
immunogenicity
[103].
Good [103, 133]
and reduced
immunogenicity
[129, 130] (no
neg. effect by
corticosteroids).
A 2nd vaccine
dose achieved
good vaccine
responses
[129].
Good [103, 133]
and reduced
immunogenicity
[129] (neg. effect by
cDMARDs). A 2nd
vaccine dose
achieved good
vaccine responses
[129].
Reduced
immunogenicity [103],
but not for TNFi.
Reduced
immunogenicity [133]
for adalimumab and
infliximab, but not for
etanercept.
Reduced
immunogenicity
[129] (neg.
effect by RTX
within the past
12 weeks). A
2nd vaccine
dose achieved
good vaccine
responses.
Reduced
immunogenicity
[103].
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VAS Good
immunogenicity
[130].
Vaccination
more
immunogenic in
Takayasu
arteriitis than in
WG and BD
patients.
Reduced
immunogenicity
[103, 129], but
insufficient
evidence for a
neg. influence
by
corticosteroids.
A 2nd vaccine
dose achieved
good vaccine
responses
[129].
Reduced
immunogenicity
under MTX
[103, 129].
A 2nd vaccine
dose achieved
good vaccine
responses
Only weak
evidence for a neg.
influence by
cDMARDS other
than MTX.
Reduced
immunogenicity in
[129] (neg. effect by
leflunomide, AZA,
MMF, CYC). A 2nd
vaccine dose
achieved good
vaccine responses.
Reduced
immunogenicity [103],
but insufficient
evidence for a
negative influence by
TNFi.
Reduced
immunogenicity
[103].
Reduced
immunogenicity
(neg. effect by
RTX); a 2nd
vaccine dose
achieved good
vaccine
responses
[129].
Reduced
immunogenicity
[103].
RA Good
immunogenicity
[94, 99, 137].
Reduced
immunogenicity
in [95, 96, 138]
(no neg. effect
by
corticosteroids).
Reduced
[93–95] to good
immunogenicity
[137, 138].
Reduced
immunogenicity
compared with
MTX or TNFi
alone [96, 97].
Good [94, 95] and
moderately reduced
immunogenicity [97,
138].
Reduced
immunogenicity
under
combination of
RTX + MTX
[89].
Reduced
immunogenicity
in patients and
healthy
persons [104,
105].
Good
immunogenicity
[108, 111]. TCZ in
addition to MTX did
not significantly
reduce immune
responses further
[109].
CTD Moderate
immunogenicity
[139].
Good to
moderate
immunogenicity
[137, 139] (no
neg. effect by
corticosteroids).
In [140, 141],
trend to lower
immunogenicity
with
corticosteroids
[140].
Good to
moderate
immunogenicity
[137, 140] (no
evidence for a
neg. effect by
MTX).
Good [141] to
moderate
immunogenicity
[137, 139] (no neg.
effect by
cDMARDs).
Trend for lower
immunogenicity
under cDMARDs
[140].
SpA Good to
moderate
immunogenicity
[138, 142] (no
neg. effect by
corticosteroids).
Good to
moderate
immunogenicity
[138] (no neg.
effect by MTX).
Reduced
immunogenicity
[142].
Moderately reduced
[143] to reduced
immunogenicity [138].
Good immunogenicity
under etanercept
[142].
Pneumococcal
poly-
saccharide
VAS
RA Good
immunogenicity
[93].
Reduced
immunogenicity
[93, 144].
Good immunogenicity
[93, 144].
Severely
reduced
immunogenicity
(10% pos.
antibody
responses),
effect more
enhanced
under RTX/
MTX
combination
(0% positive
antibody
responses)
[145].
Severely
reduced
immunogenicity
(17.6%
developed
positive
antibody
responses)
[145].
CTD
SpA Reduced
immunogenicity
[144].
Good [144] and
severely reduced
immunogenicity [147].
Pneumococcal
conjugate
VAS
RA Good
immunogenicity
[148].
Good
immunogenicity
[88].
Reduced
immunogenicity
[89].
Reduced
immunogenicity
[89] and good
immune response
[88].
Reduced
immunogenicity
under MTX,
RTX did not
reduce antibody
responses
further [89].
Immune
responses
reduced in
healthy
subjects [104].
TCZ in addition to
MTX did not
significantly reduce
immune responses
further [109].
CTD Good [148] and
reduced [149]
immunogenicity.
Trend to
decreased
antibody
responses for
corticosteroids
[140].
Moderate
immunogenicity,
[140] (no
evidence for a
neg. effect by
MTX).
Trend to decreased
antibody responses
for cDMARDs [140].
Tetanus
SpA no data
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VAS no data
Diphtheria no data
Polio no data
Pertussis no data
RA 72% of
travellers with
several IMIDs
developed a
protective
response
(number of
vaccine doses
not specified)
[150].
57% of
travellers with
several
immune-
compromising
conditions
developed
protective
responses
[150].
≥20 mIU/ml:
6%; ≥10 mIU/
ml: 6%
protected after
1 dose [92]. In
a third study
(underlying
disease not
specified):
seroprotection
rates 62% after
1 dose, 98%
after 2 doses
[151].
Good
immunogenicity in
IMID patients taking
mercaptopurine
derivatives (e.g.
AZA). Not
immunogenic under
tacrolimus (n = 2)
[150]. In [151],
(underlying disease
not specified): sero-
protection rates:
62% after 1 dose,
98% after 2 doses
for AZA, and 67%
after 1 dose and
100% after 2
vaccine doses for
other
immunosuppressive
therapies.
≥20 mIU/ml:
5% protection
after 1 dose
after 1 month;
≥10 mIU/ml:
15% protection
after 1 dose
[92].
20% of
travellers with
IMIDs did not
develop a
protective
response
[150]
≥20 mIU/ml:
20%
protection
after 1 dose
after 1 month;
≥10 mIU/ml:
73%
protected
after 1
vaccine dose
[92].
In patients
under TNFi
therapy
(underlying
disease not
specified):
seroprotection
rates were
46% after 1
dose; 79%
after 2 doses
[151].
Seroprotection
rates were 67%
after 1 dose and
100% after 2
vaccine doses
(underlying disease
not specified) for
other
immunosuppressive
therapies (incl.
cytostatics,
leflunomide,
interferon,
tacrolimus,
cyclosporine,
natalizumab,
tocilizumab (n =
1)) [151].
CTD no data
SpA no data
Hepatitis A
VAS no data
RA Moderate
immunogenicity
(68% antibody
levels >10 IU/l)
after 3 doses
[152] (patients
under treatment
with NSAIDs,
prednisone,
HCQ, MTX,
AZA, gold,
sulfasalazine)
Moderate
immunogenicity
(68% antibody
levels >10 IU/l)
after 3 doses
[152] (patients
under treatment
with NSAIDs,
prednisone,
HCQ, MTX,
AZA, gold,
sulfasalazine)
Moderate
immunogenicity
(68% antibody
levels >10 IU/l)
after 3 doses [152]
(patients under
treatment with
NSAIDs,
prednisone, HCQ,
MTX, AZA, gold,
sulfasalazine).
CTD Good
immunogenicity;
seroconversion
in 93% [153].
2/28 (the
remaining 7%)
patients
seroconverted
after a 4th
dose.
Hepatitis B
SpA Severely
reduced
immune
responses
[143, 147],
only 4/20
(22.2%)
raised a
robust
response
[143].
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VAS Good
immunogenicity;
seroconversion
in 93% in
patients with
BD [154].
Patients were
treated with
colchicine.
RA no data
CTD Good
immunogenicity
[140], trend to
decreased
antibody
responses for
steroids.
Good
immunogenicity
[140], trend to
decreased antibody
responses for AZA
and CYC.
SpA no data
Haemophilus
influenzae b
VAS no data
RA no data
CTD Reasonably
immunogenic,
prednisolone
had a negative
effect on HPV
16 titres [83].
Reasonably
immunogenic, MMF
had a negative
effect on HPV6,
HPV16 and HPV18
titres [83].
SpA no data
HPV
VAS no data
Tick-borne encephalitis no data
Rabies no data
Japanese encephalitis no data
Meningococcal vaccine (polysaccharide or conjugate) no data
Typhoid fever (inactivated or oral live) no data
Cholera no data
AZA = azathioprine; BD = Behςet’s Disease; cDMARDs = classical disease-modifying antirheumatic drugs; CTD = connective tissue disease; CYC = cyclophosphamide; GMT = geometric mean titre;
HC = healthy control; Hib = Haemophilus influenzae type b; HPV = Human Papilloma Virus; HCQ = hydroxychloroquine; IMID = immune-mediated inflammatory disease; MMF = mycophenolate
mofetil; MTX = methotrexate; NSAIDs = nonsteroidal anti-inflammatory drugs; RA = rheumatoid arthritis; RTX = rituximab; SOT = solid organ transplant; SpA = spondyloarthritis; TCZ = tocilizumab;
TNF = tumour necrosis factor; TNFi = tumour necrosis factor inhibitor; VAS = vasculitis; WG = Wegener’s granulomatosis.; Other DMARDs include all classical DMARDs apart from methotrexate
(azathioprine, cyclophosphamide, cyclosporine, gold, hydroxychloroquine, leflunomide, mycophenolate mofetil, sulfasalazine, tacrolimus).
recommended. As vaccines may not be sufficiently im-
munogenic under immunosuppressive treatment, serologic
testing is indicated, especially after a primary vaccination
course (see section 11). Some further relevant aspects on
timing of vaccination under different immunosuppressive
agents can be found in section 8.
7. In general, live vaccines should be avoided in AIIRD
patients under treatment with a systemic
immunosuppressive effect (QoE: grade of evidence not
possible, SoR: strong)
Scientific data on live vaccinations are scarce in AIIRD pa-
tients and are mostly available on re-vaccinations (table 2).
In general, live vaccines should be avoided during system-
ic immunosuppressive therapy, but some exceptions apply
(table 3). An individual patient approach may be necessary,
taking into account the underlying disease, the medication,
the replication capacity of the vaccine and the risk of infec-
tion. If a live vaccine is indicated under immunosuppress-
ive treatment, a specialist (e.g. vaccination / travel medi-
cine specialist / immunologist) should be consulted.
Consider replication capacity of live vaccines
The administration of live vaccines to immunodeficient pa-
tients bears the risk of replication of the attenuated vaccine
micro-organism and clinically manifest infection. Sever-
al case reports on severe side effects after the administra-
tion of a live vaccine to patients under immunosuppressive
treatment have been published [155, 156].
Some live vaccines (e.g. yellow fever vaccine) have a
greater replication capacity than others (e.g. varicella)
[157–160]. When deciding on whether a person under im-
munosuppressive treatment can receive a live vaccine, the
replication capacity, the relative risks of different live vac-
cines as well as the availability of an antiviral agent, im-
munoglobulin or antibiotic treatment must be taken into ac-
count (table 4).
Consider risk of infection
When evaluating the administration of a live vaccine to an
immunocompromised patient, the risk of exposure has to
be taken into account. In Switzerland, for instance, wild
type varicella, mumps, measles and rubella viruses are
present, and exposure cannot be safely avoided. Contrary
to this, exposure to yellow fever is a travel-associated risk,
which can usually be avoided.
A vaccination / travel medicine specialist should be
contacted before administration of a live vaccine
If an AIIRD patient is under immunosuppressive therapy
and immunity towards measles, rubella, varicella and yel-
low fever is unknown (for yellow fever only if a previous
vaccination was performed), specific serological tests
should be performed. If the patient is not immune against
measles, rubella and varicella and cannot be vaccinated
owing to the immunosuppressive therapy, the vaccination
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status of their household and other close contacts should be
checked. Please see sections 12, 13 and 14 for detailed re-
commendations.
If a live vaccine is indicated but the extent of the phar-
macological immunosuppression is unclear, the specialist
can adopt the following approach: administer an inactiv-
ated vaccine containing a neoantigen (e.g. hepatitis A vac-
cine) and measure the humoral immune response after 4–6
weeks, together with the number of CD4+ cells. If the
humoral immune response to the inactivated vaccine is sat-
isfactory and the CD4+ cells are over a specific threshold
(200 cells/µl), a live vaccine may be administered (fig. 1).
8. Depending on the drug, different intervals between
immunosuppressive treatment and vaccination are
advised (QoE: very low, SoR: weak)
Inactivated vaccines
Safety
Figure 1
Scheme for the application of a live vaccine when the extent of the
pharmacological immunosuppression is unclear.
From safety aspects, inactivated vaccines can be given at
any timepoint during immunosuppressive therapy.
Immunogenicity
For several medications, the timing of vaccination in rela-
tion to medication appears to have an effect on immuno-
genicity (see also section 6) and timing of inactivated vac-
cination in relation to immunosuppressive treatment should
be considered (table 5).
Live vaccines
For safety reasons, it is advisable to wait for a certain time
period after cessation or interruption of an immunosup-
pressive agent before administrating a live vaccine.
The duration of the immunosuppressive effect depends on
(i) the half-life of the active drug component and (ii) re-
covery from the immunological effect (e.g. B and/or T cell
depletion). For most immunosuppressive medications this
timepoint has not been clearly defined [87].
There are some general recommendations summarised in
table 6.
9. Recommended vaccinations
General basic vaccinations are recommended for patients
with autoimmune inflammatory rheumatic diseases (QoE:
moderate, SoR: strong)
Generally recommended vaccinations include immunisa-
tions against tetanus, diphtheria, polio, pertussis, hepatitis
B, Haemophilus influenza b, mumps, measles, rubella and
varicella. All these vaccinations are also recommended for
Table 2: Published studies on live vaccines in patients with rheumatic diseases.
MMR Yellow fever Varicella Herpes zoster
MMR revaccination was safe and
immunogenic in a prospective nested
case-control study in 15 children with
JIA, partly under treatment with MTX
alone or in combination with etanercept
[161].
MMR revaccination was safe in a
retrospective cohort study in children with
JRD (n = 207), partly treated with MTX (n
= 49) [161, 162].
In one randomised controlled trial, MMR
revaccination was safe and
immunogenic in 63 children with JIA
including 29 taking MTX, 1 leflunomide, 6
TNFi (not infliximab) and 3 anakinra. The
biologicals were interrupted for 5 half-
lives before vaccination [163].
In a prospective observational study,
MMR vaccination was given to 28
patients with JRD. Out of these, 19 were
under therapy with MTX. Out of these 19,
five additionally received prednisone and
two were on TNFi. In 2/28, MMR was a
first-time vaccination. In one of them
(therapy with MTX and corticosteroids)
fever and a skin rash appeared 20 days
after vaccination. It was concluded that
the rash was part of the disease activity
(systemic JIA) rather than a side effect of
vaccination (personal communication). In
all others, vaccination was safe [164].
Safety of YF revaccination was
demonstrated in two case series [165,
166] (Scheinberg et al.: 19 patients all
under infliximab treatment, MTX, no
corticosteroids, de Mota et al.: 70
patients, concomitant treatment MTX,
corticosteroids, nonbiological DMARDS).
Immunogenicity was explored in [165] in
patients treated with infliximab/MTX. YF
revaccination was immunogenic, but a
trend to lower antibody responses was
observed compared with healthy
persons.
In a prospective cohort study, 19 patients
under long-term low dose or short-term
high-dose corticosteroid treatment were
vaccinated for the first time against YF,
and 15 were revaccinated. Apart from
more local side effects, vaccination was
safe and immunogenic [167].
VZV first-time vaccination was safe in
[168]; in this prospective study, 20
children with JRD (20 varicella-naive and
5 with positive varicella titres) under MTX
treatment, corticosteroids and other
DMARDs were vaccinated once.
Seroconversion rates were slightly
reduced compared with controls.
In a prospective study, 50 patients with
JRD and without VZV history (all under
medication with MTX [dosage range
10–27 mg/m2/week], 23 also on
prednisone, 5 on TNFi) were vaccinated
against VZV, 32 of them received 2
doses. First-time vaccination was safe.
Seroconversion rates were 50% after 1
dose, 87% after 2 doses. All 4 who did
not seroconvert received TNFi. 2 who
were vaccinated once and were
seronegative after 1 y developed
varicella [169].
In a prospective controlled study, 26 SLE
patients with VZV history received VZV
vaccination. It was well tolerated and
antibody production was appropriate;
IFNγ-producing cells were lower than in
HCs. No HZ cases occurred in the
vaccinated group, but 4 cases occurred
in the unvaccinated group [170].
HZ vaccine was safe and immunogenic
in two large retrospective cohort studies
([i] n = 463,541 IMID patients, out of
these 18,683 patients were vaccinated;
[ii] n = 44,115 patients where 551
received HZ vaccination). Patients
included had different autoimmune
diseases under treatment with
nonbiological DMARDs (MTX, HCQ,
sulfasalazine, AZA, leflunomide,
ciclosporin, 6-mercaptopurine), and oral
glucocorticoids, as well as biologicals
(incl. TNFi, abatacept, RTX) [171, 172]. It
was not specified whether a history of
previous varicella infection or vaccination
was taken before HZ vaccine
administration.
One prospective, controlled study was
performed in 10 SLE patients under
treatment with prednisone ≤10 mg daily,
HCQ ≤6.5 mg/kg daily, MTX ≤20 mg/
weekly, AZA ≤150 mg daily, (no other
medications were allowed, incl. biological
agents). All were seropositive for VZV.
Vaccination was safe, but slightly less
immunogenic than in control subjects
[173].
AZA = azathioprine; HCQ = hydroxychloroquine; HC = healthy control; HZ = herpes zoster; IFN = interferon; IMID = immune-mediated inflammatory disease; JIA = juvenile
idiopathic arthritis; JRD = juvenile rheumatic disease; MMR = mumps; measles; rubella; MTX = methotrexate; RTX = rituximab; SLE = systemic lupus erythematosus; TNF
= tumour necrosis factor; TNFi = tumour necrosis factor inhibitor; VZV = varicella zoster virus; YF = yellow fever.
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AIIRD patients in accordance with general Swiss vaccina-
tion recommendations [177].
It appears reasonable to give tetanus/diphtheria booster
vaccinations every 10 years in immunocompromised per-
sons, although this has not been studied. Regarding the live
Table 3: Live vaccines during immunosuppressive therapy.
Therapeutic agent Herpes zoster / varicella vaccination Mumps, measles, rubella (MMR),
yellow fever vaccination
Low-dose systemic or topical corticosteroids:
• Short- or long-term daily or alternate-day therapy with <20 mg of prednisone or
equivalent
• Glucocorticosteroid replacement therapy in adrenal insufficiency / topical steroids
(airways, skin, ears, or eyes)
• Intra-articular, bursal, or tendon injection of steroids
Sulfasalazine
Hydroxychloroquine
No restrictions* No restrictions*
≤0.4 mg/kg/week
(≤20 mg/week): vaccination possible*
≤0.4 mg/kg/week
(≤20 mg/week): vaccination possible*†
Methotrexate
>0.4 mg/kg/week
(>20 mg/week): contraindication
>0.4 mg/kg/week
(>20 mg/week): contraindication
≤3.0 mg/kg/day:
vaccination possible*
Azathioprine¶
>3.0 mg/kg/day: contraindication
Contraindication
≤1.5 mg/kg day:
vaccination possible*
6-Mercaptopurine§
>1.5 mg/kg/day: contraindication
Contraindication
Abatacept
Adalimumab
Anakinra
Certolizumab
Cyclosporine A
Cyclophosphamide
Etanercept
Golimumab
High-dose systemic steroids (≥20 mg per day of prednisone or equivalent for >2
weeks)
Infliximab
Leflunomide
Mycophenolate mofetil
Rituximab
Tacrolimus
Tocilizumab
Ustekinumab
Contraindication Contraindication
In general, live vaccines should be avoided in AIIRD patients under systemic immunosuppressive therapy. Some exceptions apply.
* This recommendation is provided for patients taking a single immunosuppressant, not for combination therapy. In the case of a combination therapy the
immunosuppressive effect can be enhanced and live vaccines may be contraindicated.
† Live vaccination generally contraindicated if methotrexate dosage >0.4 mg/kg/week or >20 mg/week. Only varicella and herpes zoster: vaccination possible if ≤0.4 mg/kg/
week or ≤20 mg/week to prevent varicella infection or reactivation. MMR, yellow fever: in clinically stable cases, these live vaccines can be given during low dosage
therapy: methotrexate ≤0.4 mg/kg/week or ≤20 mg/week [174] (QoE: grade of evidence not possible, SoR: weak).
In the vaccination clinic of Service de Médecine Tropicale et Humanitaire, Hôpitaux Universitaires de Genève and the Swiss Tropical and Public Health Institute, the
administration of live vaccines (including yellow fever) under low dose MTX has been clinical practice since 2006 and no severe side effects have been reported; the
recommendation will require future follow-up. Of note, during a yellow fever vaccination campaign in Peru, a >20 times risk of YEL-AVD (yellow -fever-vaccine-associated
viscerotropic disease) was found to be associated with one particular vaccine lot. Among 42,742 vaccinees who received a vaccine from this lot, 5 developed a YEL-AVD.
Amongst these was a 49-year-old female with a past history of rheumatoid arthritis and systemic lupus erythematosus as well as treatment with methotrexate and
dexamethasone starting 4 days after vaccination (dosage unknown) [175].
¶ Only varicella and herpes zoster: vaccination possible if azathioprine dosage ≤3.0 mg/kg/day to prevent varicella infection or reactivation, above this threshold or other
live vaccines: contraindicated.
§ Only varicella and herpes zoster: vaccination possible if mercaptopurine dosage ≤1.5 mg/kg/day to prevent varicella infection or re-activation, above this threshold or
other live vaccines: contraindicated.
Table 4: Replication capacity and complication risk of live vaccines.
Systemic replication capacity* Theoretical risk of complication†
Yellow fever ++++ ++
Mumps, measles, rubella ++ +
Varicella and herpes zoster + (+)
Oral typhoid vaccine (+) –
The replication capacity, relative risks of different live vaccines as well as the availability of an antiviral agent, immunoglobulin or antibiotic treatment must be considered
when deciding on whether a person under immunosuppressive treatment can be vaccinated.
* ++++ very strong systemic replication capacity, +++ strong systemic replication capacity, ++ moderate systemic replication capacity, + weak systemic replication capacity,
(+) very weak systemic replication capacity
† ++++ very strong risk of complication, +++ strong risk of complication, ++ moderate risk of complication, + weak risk of complication, (+) very weak risk of complication
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vaccines mumps, measles and rubella, the general Swiss
vaccination guidelines recommend the MMR vaccinations
(up to two doses 1 month apart) for unvaccinated persons,
or persons who were only vaccinated once and were born
after 1963.
Adults <40 years without a history of varicella infection
should be vaccinated against varicella. In the case of a neg-
ative or uncertain history of varicella infection, specific
serum antibodies can be measured [177].
MMR and varicella vaccination may not be administered
to persons taking medication with an immunosuppressive
effect (table 3); in these persons the respective serological
tests should be performed in the case of a negative/uncer-
tain disease or vaccination history.
In immunocompromised adults exposed to an increased
risk (e.g. work in kindergarten or hospital), immunity
against measles and rubella should also be checked in those
born before 1964, and in those ≥40 years also the immunity
to varicella.
Please consult sections 12, 13 and 14 for further recom-
mendations.
Vaccinations for specific risk situations (QoE: moderate,
SoR: strong)
Vaccinations against hepatitis A, meningococci, tick-borne
encephalitis and specific travel vaccinations should be per-
formed according to general Swiss vaccination recom-
mendations [177, 178]. Also in this case, as vaccines may
not be sufficiently immunogenic under immunosuppressive
treatment, serological testing is indicated, especially after
a primary vaccination course (see section 11). It has been
shown that one dose of a monovalent hepatitis A vaccina-
tion may not provide protection in patients under therapy
with methotrexate, TNF blocking agents or combination
therapy with methotrexate and TNF inhibitors [92, 179].
More than one dose before departure may be required for
protection against hepatitis A [92]. Specific recommenda-
tions apply to live vaccines (see sections 7, 8 and 12).
10. Specific vaccinations are recommended for AIIRD
patients as they may require more comprehensive
protection (QoE: moderate, SoR: strong)
Owing to an increased risk of influenza and pneumococcal
infections [31, 32, 34, 35] and associated complications,
the pneumococcal and annual seasonal influenza vaccin-
ations are recommended in AIIRD patients. Use of the
Table 5: Recommended time period between interruption of immunosuppressive therapy and administration of inactivated vaccines.
Medication Inactivated vaccine
Corticosteroids
Low-dose systemic or topical corticosteroids
• Short- or long-term daily or alternate-day therapy with <20 mg of prednisone or equivalent
• Glucocorticosteroid replacement therapy in adrenal insufficiency / topical steroids (airways, skin, ears, or eyes)
• Intra-articular, bursal, or tendon injection of steroids
High-dose systemic steroids (≥20 mg per day of prednisone or equivalent for >2 weeks)
Adalimumab
Anakinra
Azathioprine
Certolizumab
Ciclosporin
Cyclophosphamide
Etanercept
Golimumab
Hydroxychloroquine
Infliximab
Leflunomide
6-Mercaptopurine
Methotrexate
Mycophenolate mofetil
Sulfasalazine
Tacrolimus
Tocilizumab
Ustekinumab
No time lag necessary
Abatacept If possible, vaccinate shortly before abatacept
administration*
Rituximab Wait at least 6 months for revaccination and 12
months for primary vaccination, if possible
It is generally safe to administer inactivated vaccines to patients under immunosuppressive therapy; the immunogenicity may be reduced.
For most immunosuppressants, no specific time lag between interrupting the immunosuppressive agent and administration of an inactivated vaccine has to be respected.
As vaccines may not be sufficiently immunogenic under immunosuppressive treatment, serological testing 4‒6 weeks after vaccination may be indicated, especially after a
primary vaccination course. If at all possible, for immunogenicity reasons it may be advisable to respect the same time intervals for inactivated vaccines as those
recommended for live vaccines (table 6). If these time intervals can be respected, no reduced immunogenicity has to be expected.
Regarding B-cell depleting therapy, immune responses to inactivated vaccines may be insufficient when immunisation is performed within 6 months after RTX. Inactivated
vaccines should therefore be given several weeks before initiating RTX, or at least 6 months afterwards. This recommendation is not made for safety reasons, but for
immunogenicity reasons only. The recommendation is based upon the half-life of rituximab, on immunogenicity studies of inactivated vaccines as well as on CD19+ cell
measurements under rituximab therapy [113, 176]. If a vaccine is indicated within 6 months after rituximab (e.g. influenza vaccine during the influenza season), it may be
given. The immunogenicity and the duration of protection may be reduced significantly. CD19+ B cells can be measured before vaccination as the best proxy available for
the quantity of B cells in the periphery. In addition, immunoglobulin levels can be measured.
* For abatacept, it may be advisable to vaccinate shortly before abatacept application as immune responses have been shown to be severely reduced when vaccinations
were given 2 weeks after abatacept [104].
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13-valent pneumococcal conjugate vaccine (Prevenar®)
once is recommended [180]. In opposition to EULAR and
CDC recommendations [90, 181], the use of the polysac-
charide vaccine is no longer recommended (please see sec-
tion 15 for further details).
It could be demonstrated that the primary immune response
to a pneumococcal conjugate vaccine in AIIRD patients
under immunosuppressive therapy is similar to primary im-
mune responses to the polysaccharide vaccine under ther-
apy with non-biological DMARDs and TNFα blocking
therapy [93]. Treatment with methotrexate or methotrexate
in combination with TNFα blocking therapy appears to
hamper the immune response to both conjugate and poly-
saccharide pneumococcal vaccines [94–96, 144].
Because of an increased risk of herpes zoster in AIIRD pa-
tients, herpes zoster vaccination is recommended in those
aged >50 years. At the moment, herpes zoster vaccine is
not available in Switzerland. If it becomes available, the
Advisory Committee on Immunisation Practices (ACIP)
recommendations may be followed [182].
Hepatitis B infections can be more severe in AIIRD pa-
tients under immunosuppressive therapy [48] and thus vac-
cination against hepatitis B is encouraged in this patient
group.
Vaccination against HPV is recommended in female pa-
tients aged 11–14 years and should especially be encour-
aged in patients with systemic lupus erythematosus. Vac-
cination can be recommended up to the age of 26 years,
according to FOPH recommendations [46, 47, 177].
Table 6: Recommended time period between interruption of immunosuppressive therapy and administration of live vaccines.
Medication Mumps, measles, rubella (MMR) vaccine, varicella vaccine, yellow fever
vaccine
Low-dose systemic or topical corticosteroids
• Short- or long-term daily or alternate-day therapy with <20 mg of prednisone or
equivalent
glucocorticosteroid replacement therapy in adrenal insufficiency / topical steroids
(airways, skin, ears, or eyes)
• Intra-articular, bursal, or tendon injection of steroids
Sulfasalazine
Hydroxychloroquine
No pausing or time lag necessary
High-dose systemic steroids (≥20 mg per day of prednisone or equivalent for >2
weeks)
Wait at least 1 month
Etanercept Wait at least 1 month*
≤0.4 mg/kg/week
(≤20 mg/week)†
Methotrexate
>0.4 mg/ kg/ week
(>20 mg/ week): Wait at least 1–3 months¶
Abatacept
Adalimumab
Anakinra§
Azathioprine
Certolizumab
Cyclosporine
Cyclophosphamide
Golimumab
Infliximab
6-Mercaptopurine
Mycophenolate mofetil
Tacrolimus
Tocilizumab
Ustekinumab
Wait at least 3 months*
Rituximab Wait at least 12 months‡
Leflunomide Wait at least 2 years**
* As currently no data are available, these recommendations are mostly based on expert opinion and medication half-lives.
† Only varicella and herpes zoster: no time lag if methotrexate ≤0.4 mg/kg/week or ≤20 mg/week to prevent varicella infection or reactivation. Please consult table 3 for
further exceptions.
¶ According to medication half-life, 1 month is sufficient. If there is sufficient time and the clinical situation permits, wait for 3 months after interruption of methotrexate.
§ Owing to the short half-life (4–6 hours) of anakinra, live vaccines might be given earlier than 3 months after cessation of the therapy. But so far, only data on the safe and
immunogenic administration of a second MMR vaccination in three cases after cessation of anakinra for 5 half-lives have been reported [163].
‡ As currently no data are available, this recommendation is based on expert opinion, the half-life of rituximab and on immunogenicity studies of inactivated vaccines. The
reasoning for this recommendation is that if an inactivated vaccine is capable of inducing a humoral immune response after a certain time period after rituximab
administration, the immune competence will also be sufficiently restored to be able to deal with a live vaccine.CD19+ B cells should be measured at the best proxy
available for B cells in the periphery.
Immunoglobulin levels should be measured and vaccinations may only be administered if they are at a normal level
** For safety reasons, live vaccines are contraindicated for at least 2 years after leflunomide therapy. But there is a specific wash-out option with inactivated carbon or
cholestyramine: According to Sanofi Pasteur a schedule similar to the one recommended for pregnancies under leflunomide can be followed before administration of a live
vaccine: After cessation of leflunomide therapy: “washout with 8 g cholestyramine 3 times daily over 11 days or 50 g activated carbon 4 times daily over 11 days.
Independent of the washout method, the determination of the plasma level of leflunomide is necessary in two tests that are at least 14 days apart. After the first test with a
plasma level below 0.02 mg/l it is necessary to wait for another 1.5 months before fertilisation is possible”.
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11. Serology after a completed course of vaccination
should be performed in the primary course of a
vaccination – if the corresponding serological test is
available (QoE: grade of evidence not possible, SoR:
weak)
In immunosuppressed persons, the vaccine response should
be assessed 4–6 weeks after a primary course of a vaccin-
ation. In booster vaccinations, serology is not necessary as
better immune responses can be expected. The most com-
mon method for verification is the measurement of anti-
bodies to the antigens contained in the vaccine after a com-
plete course of vaccination (e.g. after the third vaccination
against tick-borne encephalitis). For certain recommended
vaccinations (diphtheria, tetanus, Haemophilus influenzae
type b, hepatitis B, pneumococccal disease, tick-borne en-
cephalitis, rabies) the protective correlates are known and
the available serological tests are capable of measuring the
vaccine-induced antibody responses (please refer to table
1 in the vaccination recommendations published by the
Swiss Federal office of Public Health for stem cell re-
cipients [183]). Other available serological tests are cap-
able of measuring immune responses after a natural infec-
tion, but are less sensitive in evaluating vaccine responses
(hepatitis A, measles, and rubella). However, a serologic-
al check is also recommended after these vaccinations.
A positive result indicates a good immune response. A
negative result after measles or rubella vaccination does
not necessarily indicate vaccine failure. Also, the gener-
ally used serological methods for varicella are often not
sensitive enough. More sensitive tests can be performed at
“Hôpitaux Universitaires de Genève” (address at the end of
the article). If serological thresholds are not reached with
a generally recommended course of vaccination, addition-
al doses may be necessary for achieving protection. In such
a case, it is recommended to check the serology again 4–6
weeks after the additional vaccine dose. It has been shown
that in AIIRD patients who had not responded to one H1N1
vaccine dose, better antibody titres and seroprotection rates
could be achieved after a second dose [129]. Similarly, in
one study, SLE patients who had not seroconverted after
three doses of hepatitis B vaccine, developed positive anti-
HBs antibodies after a fourth vaccine dose [153].
For pertussis and mumps vaccines, it has not been possible
to define a protective threshold for vaccine antibodies.
Thus, serology after these vaccines is not useful to assess
whether a person is protected. For other vaccines, such as
meningococci and human papillomavirus, no serology is
routinely available to date. Please consult section 12 for
recommendations concerning serology after yellow fever
vaccination.
If a vaccine serology is not available or reliable, an al-
ternative approach may be considered to decide whether
a vaccine could prove immunogenic in a patient under
immunosuppressive treatment: measuring basic immuno-
logy parameters by flow-cytometry in the peripheral blood
(number of circulating CD4+, CD8+ and CD19+ cells) as
well as total serum immunoglobulins, and consulting an ex-
pert.
12. If a patient is under immunosuppressive therapy
and immunity towards measles, rubella, varicella and
yellow fever is unknown, serological testing should be
performed (QoE: grade of evidence not possible, SoR:
strong)
If it is unclear whether an AIIRD patient under treatment
with immunosuppressants is protected against measles or
rubella (in the case of measles, independent of history and
vaccination status), it is advisable to test serologically for
immunity. The serology sample should be sent to a “gener-
al laboratory”. If the results are equivocal, the test should
be repeated in a reference laboratory (Laboratoire de viro-
logie, Hôpitaux Universitaires de Genève).
If it is unclear whether an AIIRD patient under treatment
with immunsupressants is protected against varicella (inde-
pendent of history and vaccination status), it is advisable
to test serologically for immunity. The serology sample
should be sent to a “general laboratory”. If the results are
equivocal the test should be repeated in a reference laborat-
ory. In this case, serum can be sent to “Laboratoire de vac-
cinologie des Hôpitaux Universitaires de Genève” where a
more sensitive test can be performed.
If an AIIRD patient under immunosuppressive therapy in-
tends to travel to a yellow fever endemic region and has
been vaccinated against yellow fever in the past, neutral-
ising antibody levels should be measured. The immunity
against yellow fever should be checked irrespective of time
point of vaccination, i.e., immunity should be checked if
the vaccination was given ≤10 years ago as the immun-
osuppressive treatment may have reduced immunity. The
immunity should also be checked if the vaccination was
administered >10 years ago, as protection may last longer
than 10 years and may still be present.
13. As the immunocompromised person may not be
protected against diseases, insist on checking
vaccination status of their household and other close
contacts (QoE: grade of evidence not possible, SoR:
strong)
To attain protection for the immunocompromised person,
the vaccination status of household members and close
contacts should also be checked. Vaccinations should be
supplemented as appropriate, especially those against
mumps, measles, rubella, varicella and influenza.
14. If the immunocompromised person is not protected
against measles and/or varicella and has contact with
an infected person, consider immunoglobulins/
antivirals (QoE: moderate, SoR: strong)
If the immunocompromised person is not protected against
measles and has contact with an infected person, intra-
venous immunoglobulins (IVIg 400 mg/kg body weight)
should be considered. In the case of exposure to chicken
pox or disseminated herpes zoster, an unimmunised, ser-
onegative AIIRD patient under immunosuppression should
receive varicella zoster immunoglobulin within 10 days.
After the receipt of immunoglobulins, the patient should be
observed for one month. In the case of signs of varicella in-
fection, antiviral treatment (e.g. aciclovir) should be given
promptly without awaiting confirmatory laboratory results
[182, 184].
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15. Always use conjugate vaccines in preference to
polysaccharide vaccines (QoE: low, SoR: strong)
Conjugate vaccines should be preferred to polysaccharide
vaccines for several reasons: the former induce higher af-
finity antibodies, longer-lasting antibody responses and
memory responses, and booster vaccinations induce even
higher antibody levels. Contrarily, after the administration
of a polysaccharide vaccine, secondary vaccination may
elicit only poor immune responses owing to a lack of
memory cells. The administration of a first dose of plain
polysaccharide vaccine may even blunt the immune re-
sponse to subsequent doses (also to a subsequent dose of a
conjugate vaccine), such that the antibody levels following
a second vaccination, and possibly the magnitude of clinic-
al protection, may be lower than following a first vaccina-
tion [180, 185].
So far, there are no data on meningococcal vaccination in
adult AIIRD patients. However, it can be concluded from
immunological concepts [186] that the meningococcal con-
jugate vaccine should also be preferred over the polysac-
charide vaccine.
16. Vaccination should preferentially be administered
during stable disease (QoE: low, SoR: weak)
Only a few studies have compared immunogenicity and
safety of vaccinations between AIIRD patients with stable
and unstable disease. Most vaccination studies in AIIRD
patients were performed in patients with stable disease.
In several studies on influenza, pandemic influenza and
pneumococcal vaccine in patients with rheumatoid arth-
ritis, spondyloarthritis, vasculitis, or connective tissue dis-
eases, no increase in side effects or disease flares, nor
decreased vaccine immunogenicity was seen when also pa-
tients with moderate or severe disease activity were in-
cluded [122, 130, 131, 135, 137].
In studies on seasonal influenza, pneumococcal, tetanus
toxoid and Haemophilus influenzae type b vaccines in SLE
patients, and one study on hepatitis B vaccination in
rheumatoid arthritis patients, the immunogenicity of the
vaccines seemed to be reduced in patients with increased
disease activity. This effect might also be attributed to the
fact that patients with higher disease activity also received
more immunosuppressive therapies [126, 140, 146, 152].
However, the numbers of patients in these studies were too
small to draw a definite conclusion.
Vaccination should therefore be preferentially administered
during stable disease, more because of concerns of reduced
immunogenicity (due to a higher level of immunosuppress-
ive therapy) than of vaccine-induced flares in patients with
active disease. This approach will also avoid the confusion
of flare-ups of the underlying disease with vaccine-induced
side effects.
Discussion
The recommendations for vaccination in patients with
autoimmune inflammatory rheumatic diseases presented in
this article have been formulated after an evaluation of the
currently available data in the literature and after several
rounds of consultations of experts in the fields of rheum-
atology, immunology, infectious diseases, vaccinology and
travel medicine.
Most of the data available refer to influenza and pneumo-
coccal vaccination; for other inactivated vaccines available
evidence is still scarce. However, based on the data one
can conclude that inactivated vaccines are (i) safe in AIIRD
patients with or without immunosuppressive therapy and
that (ii) under most immunosuppressive therapies vaccines
induce good to moderate immune responses. Severely re-
duced immunogenicity can be found under methotrexate,
methotrexate plus TNF inhibitor combination therapy,
abatacept and, especially, rituximab. However, it is unclear
whether the humoral immune responses (most commonly
used as surrogates of protection in vaccination studies) cor-
relate with protection. Only very few studies used actual
“effectiveness” of vaccinations as an endpoint [31, 32,
187].
Few studies on live vaccination under immunosuppression
could be identified, most of them examined revaccination
under immunosuppressive therapy. Thus recommendations
on live vaccinations were kept rather conservative.
We have attempted to give less restrictive recommenda-
tions regarding live vaccines under low-dose methotrexate
therapy, backed up by the growing clinical experience with
live vaccinations under this medication. Additionally, in
this document, advice for specialists is given on specific
approaches, which can guide the decision process of ad-
ministering a live vaccine in unclear situations (section 7).
The reader of these recommendations should keep in mind
that the majority of recommendations given in this article
are based on clinical experience and expert opinion as sci-
entific data are still scarce on many aspects.
More evidence regarding the immunogenicity and safety
of vaccinations in AIIRD patients under various therapies
is urgently needed. Vaccination recommendations need to
be updated on a regular basis, as more scientific data re-
garding vaccination efficacy and safety, emergent infec-
tious threats, new vaccines as well as new immunosup-
pressive therapies will become available.
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Figures (large format)
Figure 1
Scheme for the application of a live vaccine when the extent of the pharmacological immunosuppression is unclear.
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